双歧杆菌BB-12治疗婴幼儿腹泻临床疗效对照研究

发布时间：2018-06-23 07:06

本文选题：双歧杆菌BB- + 枯草杆菌二联活菌　；参考：《中国实用儿科杂志》2017年07期

【摘要】：目的评估双歧杆菌BB-12对婴幼儿腹泻治疗的有效性和安全性。方法对2015年12月至2016年8月吉林大学白求恩第一医院小儿消化内科诊治的120例腹泻患儿,采用随机、单盲方法,分为双歧杆菌BB-12治疗组、枯草杆菌二联活菌阳性对照组、未添加益生菌的安慰剂组,各40例。均配合蒙脱石散及补液等对症治疗,比较各组病例临床资料并进行分析。结果治疗组的显效率及有效率分别为37.50%、52.50%,阳性对照组为42.50%、42.50%,安慰剂组为17.50%、52.50%,差异有统计学意义(P0.05),治疗组与阳性对照组相比,差异无统计学意义(P0.05)。3组大便次数:第4天治疗组(3.10±1.41)次/d、阳性对照组(3.05±1.63)次/d、安慰剂组(3.93±1.91)次/d;第7天治疗组(1.45±0.64)次/d、阳性对照组(1.43±0.90)次/d、安慰剂组(1.95±1.30)次/d,3组较治疗前均明显减少,差异有统计学意义(P0.05)。但治疗组与阳性对照组相比,差异无统计学意义(P0.05),与安慰剂组比较差异有统计学意义(P0.05)。3组患儿治疗后腹泻好转所需天数方面,治疗组、阳性对照组及安慰剂组分别为(4.20±1.32)d、(4.40±1.37)d、(5.18±1.57)d,3组差异有统计学意义(P0.05),但治疗组与阳性对照组相比,差异无统计学意义(P0.05)。结论双歧杆菌BB-12治疗婴幼儿腹泻安全有效。
[Abstract]:Objective to evaluate the efficacy and safety of Bifidobacterium B-12 in the treatment of infantile diarrhea. Methods from December 2015 to August 2016, 120 children with diarrhea were treated in Department of Pediatric Gastroenterology, Bai Qiuen first Hospital, Jilin University. The patients were randomly divided into two groups: BB-12 treatment group and Bacillus subtilis positive control group. There were 40 cases in the placebo group without probiotics. All patients were treated with montmorillonite powder and rehydration. The clinical data of each group were compared and analyzed. Results the effective rate and effective rate of the treatment group were 37.50 and 52.50, respectively, the positive control group was 42.50 and the placebo group was 17.50 and 52.50, the difference was statistically significant (P0.05), and the difference between the treatment group and the positive control group was significant (P0.05). There was no significant difference in the number of defecation in the treatment group (3.10 卤1.41) times on the 4th day, in the positive control group (3.05 卤1.63) times / r / d, in the placebo group (3.93 卤1.91) times / r / d, on the 7th day in the treatment group (1.45 卤0.64) / r / d, in the positive control group (1.43 卤0.90) / r / d, and in the placebo group (1.95 卤1.30) / rpm / d, respectively. The difference was statistically significant (P0.05). However, there was no significant difference between the treatment group and the positive control group (P0.05). There was a significant difference between the treatment group and the placebo group (P0.05). The difference of positive control group and placebo group was (4.20 卤1.32) d, (4.40 卤1.37) d, (5.18 卤1.57) dai (P0.05), but there was no significant difference between the treatment group and the positive control group (P0.05). Conclusion Bifidobacterium BB-12 is safe and effective in the treatment of infantile diarrhea.
【作者单位】：吉林大学白求恩第一医院小儿消化内科;上海交通大学医学院附属上海儿童医学中心过敏免疫科;
【分类号】：R725.7

【相似文献】